Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib effectively treats severe alopecia areata and is safe.

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

Early diagnosis, innovative treatments, and considering systemic conditions are crucial in dermatological care.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Combining glucocorticoids with immunosuppressants like cyclophosphamide improves remission and reduces relapse in pemphigus patients.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

Janus kinase inhibitors may help treat lichen planopilaris.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.